You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
明德生物(002932.SZ):前三季度淨利預增172.30%-253.70%
格隆匯 10-11 18:05

格隆匯10月11日丨明德生物(002932.SZ)披露2021年前三季度業績預吿,公司預計2021年1-9月實現歸屬於上市公司股東的淨利潤9.70億元-12.60億元,同比增長172.30%-253.70%。業績大幅預增的主要原因系:

1、公司深耕三年的急危重症信息化解決方案持續迭代升級,在基層醫療和等級醫院中滲透率逐步提高,相關收入穩步增加。報吿期內,急危重症信息化解決方案完成明德專病中心信息管理平台V4.0升級,開發了AiCare重症監護臨牀信息系統、明醫諮詢管理平台、明德專病中心信息管理平台等,並取得相關軟件著作權17項。

2、疫情爆發以來公司新增了1,500多家分子診斷等級醫療機構客户,基於國家疫情防控的要求,公司持續為上述客户提供新冠核酸檢測綜合解決方案,帶來公司新冠核酸檢測試劑及分子診斷相關儀器銷售大幅增長。

3、報吿期內,公司產品線日益完善,新獲批全自動化學發光免疫分析儀CP800、全自動熒光免疫分析儀AFT3000、乾式熒光免疫分析儀QFT9000Pro等檢測平台,並新增87項醫療器械註冊證。報吿期末,公司共持有208項醫療器械註冊證。其中,血氣診斷儀器PT1000及相關檢測試劑、化學發光免疫分析儀CF10及相關檢測試劑銷售均同比大幅增長。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account